Phaseline

Targets › CA2

CA2 (Carbonic anhydrase 2): drug programs, companies and trials

5 programs from 5 companies in 28 trials: 11 Phase 4, 8 Phase 2, 8 Phase 1, 1 Phase 3; Ophthalmology, Neurology, Metabolic and endocrine; next expected readout Dec 2026.

Catalyzes the reversible hydration of carbon dioxide. Can also hydrate cyanamide to urea. (UniProt, P00918)

Open in Phaseline: the race on CA2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TecnoquimicasPreservative-free dorzolamide-timolol-brimonidine combination
Carbonic anhydrase inhibitor (dorzolamide), beta-adrenergic antagonist (timolol), and alph
CA2, ADRB1, ADRA2APhase 4Primary Open-Angle Glaucoma (POAG)Jul 2027
University of Colorado, DenverMethazolamide
Carbonic anhydrase VII inhibitor; Carbonic anhydrase I inhibitor; Carbonic anhydrase II inhibitor
CA7, CA1, CA2, CA4Phase 4Glaucoma, Open-Angle–
Upsher-Smith LaboratoriesTopiramate
Carbonic anhydrase II inhibitor; Carbonic anhydrase IV inhibitor; Glutamate receptor ionotropic AMPA antagonist
CA2, CA4, GRIA4, GRIA3, GRIA2Phase 4Migraine Disorders; Obesity; Ménière; Liver Cirrhoses …–
ShionogiAcetazolamide
Carbonic anhydrase I inhibitor; Carbonic anhydrase II inhibitor; Carbonic anhydrase XII inhibitor
CA1, CA2, CA12, CA4Phase 2Sleep Apnea; Hypobaric Hypoxia; High Altitude Effects; Post Operative Pain …Dec 2026
Incannex HealthcareIHL-42X
Dronabinol (cannabinoid CB1/CB2 receptor agonist) combined with acetazolamide (carbonic an
CNR1, CNR2, CA2Phase 2Obstructive Sleep Apnea (OSA)Apr 2027

Conditions

Sleep Apnea (3) Obstructive Sleep Apnea (3) Glaucoma, Open-Angle (1) Primary Open-Angle Glaucoma (POAG) (1) Migraine Disorders (1) Obesity (1) Ménière (1) Liver Cirrhoses (1) Post Traumatic Stress Disorder (1) Hypobaric Hypoxia (1) High Altitude Effects (1) Post Operative Pain (1)

Modalities

small molecule (4)

Companies

University of Colorado, Denver (1) Tecnoquimicas (1) Upsher-Smith Laboratories (1) Shionogi (1) Incannex Healthcare (1)

Related targets

CA4 (3) CA1 (2) CA7 (1) ADRB1 (1) ADRA2A (1) GRIA4 (1) GRIA3 (1) GRIA2 (1) CA12 (1) CNR1 (1) CNR2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.